Lake Street initiated coverage on MDxHealth SA with a new price target
$MDXH
Medical Specialities
Health Care
Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $7.00 | Buy | Lake Street |
| 5/31/2023 | $7.00 | Outperform | TD Cowen |
| 7/18/2022 | $18.00 | Outperform | Oppenheimer |
4 - MDxHealth SA (0001872529) (Issuer)
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We generated another strong topline performance in the third quarter of 2024, with year-over-year revenue growth of 21%, or 27% when adjusted for a ba
MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. Title:MDxHealth Presents Third Quarter 2024 Financial Results and Corporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:November 6,
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value ("Ordinary Shares") in a registered public offering (the "Offering") at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company
Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00
TD Cowen initiated coverage of MDxHealth SA with a rating of Outperform and set a new price target of $7.00
Oppenheimer resumed coverage of MDxHealth SA with a rating of Outperform and set a new price target of $18.00
6-K - MDxHealth SA (0001872529) (Filer)
6-K - MDxHealth SA (0001872529) (Filer)
SCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie
Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert's resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity, CEO of mdxhealth, commented: "On behalf of the Board of Directors and the employees of mdxhealth, I would like to thank Jan for his suppor
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We generated another strong topline performance in the third quarter of 2024, with year-over-year revenue growth of 21%, or 27% when adjusted for a ba
MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. Title:MDxHealth Presents Third Quarter 2024 Financial Results and Corporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:November 6,
MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 millionYear-over-year H1 revenues increase by 34% to 42.0 millionConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the second quarter and half year ended June 30, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "Our strong topline growth of 32% for the second quarter reflects our commercial team's execution even against our strongest quarter of 2023 for bo
MDxHealth (NASDAQ:MDXH) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.30) by 3.33 percent. The company reported quarterly sales of $19.834 million which beat the analyst consensus estimate of $18.209 million by 8.92 percent. This is a 34.93 percent increase over sales of $14.700 million the same period last year.
SC 13G - MDxHealth SA (0001872529) (Subject)
SC 13D/A - MDxHealth SA (0001872529) (Subject)
SC 13G - MDxHealth SA (0001872529) (Subject)